Completed PHASE3 INTERVENTIONAL 4-arm NCT01912456

A Study to Evaluate the Clinical Efficacy and Safety of Subcutaneously Administered C1-esterase Inhibitor in the Prevention of Hereditary Angioedema

A Double-blind, Randomized, Placebo-controlled, Cross-over Study to Evaluate the Clinical Efficacy and Safety of Subcutaneous Administration of Human Plasma-derived C1-esterase Inhibitor in the Prophylactic Treatment of Hereditary Angioedema

Sponsor: CSL Behring

Conditions Hereditary Angioedema Types I and II

Interventions Higher-volume C1-esterase inhibitor Higher-volume placebo Low-volume C1-esterase inhibitor Low-volume placebo

Updated 11 times since 2017 Last updated: Jan 11, 2021 Started: Jan 31, 2014 Primary completion: Oct 31, 2015 Completion: Oct 31, 2015

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Hereditary Angioedema Types I and II, this trial is completed. The trial is conducted by CSL Behring and has accumulated 11 data snapshots since 2014. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

11 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Feb 2021 — Jul 2024 [monthly]

Completed PHASE3
Jan 2021 — Feb 2021 [monthly]

Completed PHASE3

▶ Show 6 earlier versions

Jun 2018 — Jan 2021 [monthly]

Completed PHASE3
Sep 2017 — Jun 2018 [monthly]

Completed PHASE3
Jul 2017 — Sep 2017 [monthly]

Completed PHASE3
May 2017 — Jul 2017 [monthly]

Completed PHASE3
Feb 2017 — May 2017 [monthly]

Completed PHASE3
Jan 2017 — Feb 2017 [monthly]

Completed PHASE3

First recorded

Jan 2014

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

CSL Behring

Data source: CSL Behring

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Barcelona, Spain , Bell Gardens, United States , Birmingham, United States , Boston, United States , Brighton, United Kingdom , Budapest, Hungary , Campbelltown, Australia , Catania, Italy , Chevy Chase, United States , Cincinnati, United States and 28 more locations